Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Efficacy and Safety of Insulin Detemir in Combination With Insulin Aspart and Biphasic Insulin Aspart 30 in Type 2 Diabetes (PreFER)

This study has been completed.
Information provided by (Responsible Party):
Novo Nordisk A/S Identifier:
First received: January 17, 2008
Last updated: February 22, 2017
Last verified: February 2017

This trial is conducted in Europe.

The aim of this trial is to investigate the efficacy and safety of an intensified treatment regimen with preprandial insulin aspart and insulin detemir once or twice daily to a more convenient regimen with biphasic insulin aspart 30 twice daily on blood glucose control in subjects with type 2 diabetes.

Condition Intervention Phase
Diabetes Mellitus, Type 2
Drug: insulin detemir
Drug: insulin aspart
Device: biphasic insulin aspart
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: Comparison of Efficacy and Safety of Insulin Detemir in Combination With Insulin Aspart and Biphasic Insulin Aspart 30 in Type 2 Diabetes Mellitus

Resource links provided by NLM:

Further study details as provided by Novo Nordisk A/S:

Primary Outcome Measures:
  • HbA1c [ Time Frame: after 6 months of treatment ]

Secondary Outcome Measures:
  • Incidence of hypoglycaemic episodes
  • Adverse events
  • Difference of HbA1c change between the two groups [ Time Frame: after 13 weeks of treatment ]
  • Fasting plasma glucose of treatment [ Time Frame: after 13 and 26 weeks ]
  • Change in weight

Enrollment: 719
Actual Study Start Date: December 2, 2003
Study Completion Date: March 3, 2005
Primary Completion Date: March 3, 2005 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: insulin detemir
    Other Name: Levemir
    Drug: insulin aspart Device: biphasic insulin aspart

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Type 2 diabetes
  • Duration of type 2 diabetes for at least 6 months since diagnosis
  • Current treatment with one or two oral antidiabetic drugs for at least 3 months or with one or two oral antidiabetic drugs, given for at least 3 months in combination with intermediate or long-acting insulin/insulin analogue once daily
  • BMI below 40 kg/m2
  • HbA1c between 7-12%
  • Able and willing to perform self-monitoring of capillary blood glucose

Exclusion Criteria:

  • Current antidiabetic treatment with combination of three or more oral antidiabetic drugs
  • Previous treatment with short-acting human insulin, short-acting insulin analogue or biphasic insulin/insulin analogue within the last 6 months (7 days or less within the last 6 months is allowed)
  • Known hypoglycaemia unawareness or recurrent major hypoglycaemia, as judged by the Investigator
  • Known or suspected allergy to trial product or related products
  • Pregnancy, breast-feeding, the intention of becoming pregnant or judged to be using inadequate contraceptive measures
  • Receipt of any investigational drug within 4 weeks prior to this trial
  • Previous participation in this trial
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00605020

  Show 127 Study Locations
Sponsors and Collaborators
Novo Nordisk A/S
Study Director: Global Clinical Registry (GCR, 1452) Novo Nordisk A/S
  More Information

Additional Information:
Responsible Party: Novo Nordisk A/S Identifier: NCT00605020     History of Changes
Other Study ID Numbers: NN304-1558
Study First Received: January 17, 2008
Last Updated: February 22, 2017

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Insulin, Globin Zinc
Insulin degludec, insulin aspart drug combination
Insulin aspart, insulin aspart protamine drug combination 30:70
Insulin Aspart
Insulin, Long-Acting
Insulin, Isophane
Biphasic Insulins
Insulin Detemir
Hypoglycemic Agents
Physiological Effects of Drugs processed this record on May 25, 2017